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Use of FK 506 in Pediatric Patients 
A.G. Tzakis, J.J. Fung. S. Todo, J. Reyes. M. Green. and T.E. Starzl 
PK 506 is an immunosuppressive drug that holds par· ticular promise for pediatric patients because of its 
potency. relatively low toxicity. and simplicity of 
administration.1.2 Above all advantages is elimination of 
the need for adjuvant steroid therapy in the majority of 
cases. It was introduced for clinical trials in pediatric 
patients in September 1989. We report here our total 
experience with FK 506 in pediatric recipients of com· 
monly transplanted organs up to May I. 1990 with fol· 
low-up to August I. 1990. In addition. experience with new 
applications of FK 506 is included. A total of 74 pediatric 
patients were treated for the diverse indications summa· 
rized in Tables 1 to 4. 
THERAPEUTIC PRINCIPLES 
When needed IV. the FK 506 dose was 0.15 mglkgld given 
as a slow IV infusion. The starting oral dose was 0.15 
mglkg twice per day. At the time of conversion from IV to 
oral dosing. one day of overlap was usually allowed. 1·4 
Prednisone was administered at 20 mgld for heavier 
children or \0 mgld for patients lighter than 10 kg. The 
steroids were rapidly tapered and discontinued when the 
graft function was stable. Augmented FK 506. increased 
steroids. or OKT3 were given if rejection occurred. 
LIVER TRANSPLANTATION 
Primary Liver Transplantation 
Thirty patients underwent liver transplantation for the first 
time under FK 506 (Table I). Three died. The deaths were 
due to tension hemothorax after a central venous line 
placement intraoperatively (I case). nonreversal of hepatic 
coma (I case) and cytomegalovirus (CMV) pneumonitis (J 
case). Three of the children required retransplantation. 
two for hepatic artery thrombosis and one for primary graft 
dysfunction. Updated clinical data are shown in Table I. 
At 90 days posttransplant. 21 (77.7%) of the patients are 
steroid free and the average daily prednisone dose for the 
whole surviving group is 0.83 mgld (Table 1). The rate of 
removal from prednisone is shown in Fig I. 
Liver Transplant Rescue 
Twenty-six patients who had either early or late rejections 
on conventional immunosuppression were treated with FK 
506 as described elsewhere.4 •5 Three of these patients died 
of systemic fungal infection (one case). multifocal bron· 
chopneumonia complicating cystic fibrosis (one case). and 
tracheostomy failure and respiratory arrest after retrans-
plantation. 
Seven of these 26 patients required retransplantation. 
but in five of the seven examples. the patients were placed 
Table 1. Pediatric Liver Transplantation 
Pnmary Rescue 
No. 30 26 
Age (y, mean) 4.2 a.7 
Follow-up (d. mean) 150 1SO 
Mortality 3 3 
Retransplantation 3 7" 
Current FK 506 dose (mglkgld. orally) 0.33 0.24 
Current prednisone dose (mgld) 0.83 1.6 
Patients onloff prednisone 6121 7/16 
No. of patients on antihypertensive 0 a1 
medications 
Total bilirubin (mgldL) 0.4 0.46* 
SGOT(IU) 77 79t 
BUN (mg/dL) 20 24§ 
Creatinine (mean) 0.5 0.92 
Abbr8V1aUons: SGOr. SBfUm glutamic-oxalocetlc transaminase; BUN. blOOd 
urea nrtrogen. 
'rlVe patients wera placed on FK 506 at the time of relransplantallon. 
1Filteen patents were on antIhypertensive medicatIOnS befora rescue. 
*Mean total bilirubin. SGOT before rescue: 4.7 mgldL. 395 IU. 
§Mean BUN. craatinlne before rescue: 23 mgldL. 0.8 mgldL. 
on FK 506 at the time of retransplantation after conven-
tional therapy had failed. 
Relevant clinical data are shown in Table I. Steroids 
have been stopped in 16 of the 23 surviving patients: many 
were steroid toxic previously because of efforts with 
augmented prednisone doses to retain the grafts. 
HEART TRANSPLANTATION 
Primary Heart TransplantatIon 
Seven primary heart transplant recipients were treated 
with FK 506.6 .7 The only death was of a patient who was 
severely immunocompromised from lymphocyte depletion 
and protein-losing enteropathy. a complication of a previ-
ous Fontan operation for tricuspid atresia. The patient also 
had severe preexisting lung disease. Multiple opportunistic 
infections developed 2 months posttransplantation. 
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Fig 1. Percentage of pediatric patients on steroids after primary 
liver transplantation under FK 506. 
Heart Transplant Rescue 
Three patients who suffered intractable rejection on con-
ventional drug therapy were switched to FK 506. 7 One of 
these patients was rejecting her second graft 6 months after 
retransplantation. which was necessitated by chronic re-
jection of her first graft over a period of 7 years. All three 
patients had a good result with clinical improvement and 
an improvement in endomyocardial biopsies. Their cush-
ingoid appearance was relieved as steroids were reduced 
or stopped. 
KIDNEY TRANSPLANTATION 
A 13-year-old patient underwent primary kidney trans-
plantation on FK 506 for end-stage renal disease due to 
hemolytic uremic syndrome {HUSl.M ... There has been no 
evidence of recurrent disease in the transplanted kidney. 
HUS. at least when it is a complication of cyclosporine 
925 
(ey A). responds to FK 506.10 Renal function is satisfac-
tory (Table 2). 
HEART-LIVER TRANSPLANTATION: FK 506 FOR THE 
TREATMENT OF THE FAILING LIVER GRAFT 
A 6-year-old patient who underwent heart and liver trans-
plantation in 1984 11 developed chronic rejection and non-A 
non-B hepatitis in the liver graft. Liver function improved 
initially after switching from CyA to FK 506. Later. 
worsening of the non-A non-B hepatitis necessitated liver 
replacement in February 1990. She has developed recur-
rent non-A non-B hepatitis in her second liver graft but is 
clinically well with good liver function under treatment 
with interferon alpha OFN-a)lz (Table 2). She has never 
had a cardiac rejection and has a normal recent coronary 
angiogram. The reason for the heart-liver transplantation 
was homozygous type 2 hyperlipidemia. The serum cho-
lesterol has been lower with FK 506 than at any time 
previously (see footnote. Table 2). 
LIVER AND ISLET PRIMARY TRANSPLANTATION 
Two patients with extensive hepatic malignancies and 
regional metastases were treated with upper abdominal 
exenteration 1.1.14 followed by liver and pancreatic islet 
transplantation. One patient died. of tumor recurrence 5 
months after transplantation. The other patient is well. 
without any evidence of recurrence. and with normal liver 
function (Table 3), She is insulin free. and is the first 
unambiguous example of a human successful pancreatic 
islet transplantation. 15 •1f> 
INTRACTABLE CHRONIC GRAFT VS HOST DISEASE 
Two patients were referred to us with severe chronic graft 
vs host disease 6 months following bone marrow trans-
Table 2. FK 506 In Pediatric Extrahepatic Transplantation 
Hearl 
Kidney Heart-LIVer 
Primary Rescue Primery Rescue 
No. 7 3 1 
Age (y, mean) 7.8 16.4 13 13 
Follow·up (d, mean) 162 176 100 270 
Mortality 1 0 0 0 
Retransplantation 0 0 0 1 
Current FK 506 dose (mg/kg/d, 0.22 0.25 0.18 0.28 
orally) 
Current prednisone dose (mg/d) 0 4 10 0 
Pahents on/off prednisone 214 3/0 NA NA 
No. of patients on antlhyperten· 0 O· 0 
slve medications 
Total bilirubin (mg/dL) 0.28 0.20 0.2 o.r 
SGOT(IU) 20 51 16 79 
BUN (mgldL) 23 34.5 38 36 
Creatinine (mg/dL) 0.76 1.5 1.8 1.0 
'Two DallenlS on anbhypertenSNe medlCallOnS Defore rescue. 
'Serum chOlesterol Delorelsfler rescue: 491 mgldU183 mgJdL 
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Table 3, FK 506 In New Transplant Applications 
Uver·Pancraalic GVHD. After Bone Marrow 
Islet' Transplantation Uver·lnl8Sl1ne 
No. 2 2 1 
Age (y, mean) 15,7 8 9 3 
Follow·up (d. mean) 180 (died) 90 90 21 
220 
Mortality 0 0 
Current FK 506 dose (mgJkgJd, 0.12 0.4 0.23 0.06 (IV) 
orally) 
Current prednisone dose (mgJd) 0 10 ot 0 
No. 01 patients on antihyper1en- 0 0 0 0 
sive medications 
Total bilirubin (mgidL) 0.4 1.7 0.8* 0.4 
SGOT(IU) 29 84 99' 14 
BUN (mgJdL) 2 25 2311 52 
Creatinine (mgJdL) 0.7 0.5 1KU~ 1.5 
'Pancreatic islet function: the pabentlS insulin free. Fasllng and nontasting blood sugar: 98 mgldL. 105 rngtdL: baSal and peak C·pep1ide: 0.96. 2.8; exogenous Insulin: 
O. 
'Prednisone dose before FK 506 rescue: 150 mgld, 90 mgtd. respectively. 
*Total bilirubin before rescue: 6.3 mgtdL (patient 1). 13.8 mgtdL (pa1ient2) 
§SGOT before rescue: 113 IU (patient 1 ). 411 IU (patient 2). 
"BUN before rescue 3·mgtdL (patient 1). 22 mgtdL (pabent 2) 
'Creatinine before rescue 0.1 mgtdL (patient 1 ), 0.2 mgldL (patient 2). 
plantation for leukemia under conventional immunosup-
pression. Both had skin, intestinal. and hepatic involve-
ment. High dose FK 506 was used at first, with oral doses 
that peaked at more than 1.0 mg/kg/d (more than three 
times the usual). 
The first patient had a gradual but steady improvement 
on FK 506 and was discharged and sent home in 4 weeks 
in good condition. Steroids were tapered rapidly and 
discontinued on discharge from the hospital. 
The second patient's symptoms persisted for 2 months 
and then gradually resolved during the third month of FK 
506 treatment. The patient is still receiving 10 mgld of 
prednisone. 
In both cases. the response could be monitored objec-
tively by the slow resolution of jaundice (Table 3. see 
footnote). 
FOCAL SCLEROSING GLOMERULONEPHRITIS 
A patient with biopsy proven focal sclerosing glomerulo-
nephritis was started on FK 506 in November 1989 be-
cause of the nephrotic syndrome. which was refractory for 
13 months to continuous treatment with high doses of 
prednisone and intermittent treatment with other conven-
tional agents including cyclophosphamide. As reported 
elsewhere. 17 a complete remission was promptly achieved 
at the same time as steroid therapy was stopped (Table 4). 
LIVER-INTESTINE TRANSPLANTATION 
A 3-year-old child. who had liver failure and the short gut 
syndrome secondary to perinatal necrotising enterocolitis 
and chronic IV alimentation. received a liver and complete 
small bowel. She has normal liver function (Table 3). The 
ileostomy stoma. which appears normal. has had minimal 
evidence of rejection on biopsy. This case is included in 
the present report because of its intrinsic interest, and is 
the only one treated after the cut-off date of May I. 1990. 
Her follow-up is only 3 weeks. 
ADVERSE REACTIONS 
Adverse effects are being monitored systematically 
through clinical observation and collection of question-
naires that are given periodically to the patients and/or 
their parents. 
Several toxicity reports have been published or are 
being given at this meeting. 18·23 The side effects in children 
are similar to those in adults. 
In our 74 patients. there were four fatal infections: two 
in liver rescue patients. one in a primary heart transplant 
Table 4. FK 506 In the Treatment of Autoimmune 01 ..... : 
Rescue Treatment of Focal Sclerosing Glomerulonephl1tls. 
aca .. Report 
Age: 30 rna 
Follow-up: 6 rna Before Aller 
Edema +++ 0 
Diuretics 2 0 
Urine protein (mgld) 1406 0 
Serum cholesterol 630 146 
(mgJdL) 
Creatinine clearance 82.0 87 
(mUminl1.73 m2) 
Serum creatinine 0.3 0.3 
(mgJdL) 
BUN (mgJdL) 6 6 
Total bilirubin (mgldL) 0.5 0.4 
SGOT (lUlL) 12 25 
Note. Current FK 506 dose: 0.20 mgIkgId: current predniSone dose: 0 mgld: 
Pre-FK 506 predl\lSOlle dose: 35-70 mgtd. 
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patient, and one in a primary liver patient. Three of the 
four patients were immunocompromised when switched to 
or started on FK 506. There has been one example of 
Iymphoproliferative disease of the stomach on a liver 
rescue patient that disappeared after a reduction of the 
immunosuppression. 
Nonimmunologic side effects of FK 506 are similar to 
those of Cy A and include nephrotoxicity, neurotoxicity, 
and diabetogenicity. 24 De novo development of diabetes 
mellitus was observed in two liver rescue patients: one 
later became insulin independent after steroid withdrawal 
and reduction of the FK 506 dosage, The second patient 
still requires insulin treatment. Similar events have been 
reported in adults undergoing liver rescue, 18 
Neurologic complications such as those reported in 
adults23 have not yet been seen in infants and children. 
Transient renal dysfunction has developed mainly in liver 
rescue patients and also in the heart transplant recipients 
during the first 2 weeks after transplantation, Inappropriately 
high IV doses of FK 506 were thought to have been given as 
a management policy during this learning state of the trials. 19 
CONCLUSION 
FK 506 appears to be the most effective immunosuppres-
sive agent available today for the treatment of infants and 
children. Its use should allow improvement in graft and 
patient survival, as well as allowing an improved quality of 
steroid-free growth and development. Previously imprac-
tical kinds of transplantations should be made easier. and 
it may be possible to expand this technology to the more 
widespread treatment of autoimmune disorders in the 
pediatric population. 
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